Last reviewed · How we verify
Gentamycin/citrate, Minocycline/EDTA
This is a combination antimicrobial coating containing gentamicin (an aminoglycoside antibiotic) and minocycline (a tetracycline antibiotic) chelated with EDTA, designed to prevent bacterial biofilm formation and infection on medical devices.
This is a combination antimicrobial coating containing gentamicin (an aminoglycoside antibiotic) and minocycline (a tetracycline antibiotic) chelated with EDTA, designed to prevent bacterial biofilm formation and infection on medical devices. Used for Prevention of bacterial infection on medical devices (catheters, grafts, implants).
At a glance
| Generic name | Gentamycin/citrate, Minocycline/EDTA |
|---|---|
| Sponsor | Henry Ford Health System |
| Drug class | Antimicrobial coating / combination antibiotic |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Medical Device Infection Prevention |
| Phase | FDA-approved |
Mechanism of action
Gentamicin acts as a broad-spectrum bactericidal antibiotic that inhibits bacterial protein synthesis, while minocycline provides additional broad-spectrum coverage. EDTA (ethylenediaminetetraacetic acid) is a chelating agent that disrupts bacterial cell membranes and biofilm formation. Together, these agents are applied as a coating to medical devices to reduce infection risk.
Approved indications
- Prevention of bacterial infection on medical devices (catheters, grafts, implants)
Common side effects
- Local irritation or allergic reaction at application site
- Hypersensitivity to aminoglycosides or tetracyclines
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gentamycin/citrate, Minocycline/EDTA CI brief — competitive landscape report
- Gentamycin/citrate, Minocycline/EDTA updates RSS · CI watch RSS
- Henry Ford Health System portfolio CI